Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cladribine + homoharringtonine + cytarabine
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of cladribine, homoharringtonine, and cytarabine. This regimen has shown promising results in treating acute myeloid leukemia (AML), particularly in patients with de novo AML. The combination works through synergistic mechanisms: cladribine can increase cytarabine triphosphate levels, enhancing its effectiveness[6]. Homoharringtonine has been shown to target leukemia diseases that have switched their anti-apoptotic dependence from BCL-2 to MCL-1[1]. Together, these agents demonstrate synergistic antiproliferative effects against AML cells[2]. Clinical trials have demonstrated high remission rates, including in patients with adverse risk factors such as specific cytogenetic abnormalities.
- Other names
- CHA regimen
02
Targets
DNA polymerase familyMCL1 (Myeloid cell leukemia sequence 1)Ribosome
Beyond the preview
Go deeper on cladribine + homoharringtonine + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cladribine + homoharringtonine + cytarabine.